The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to stay up to date and inspired in their daily work. Hosted on Acast. See acast.com/privacy for more information.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
29%
Guest openness
Selective
Sign up to generate a grounded pitch for Leaders in Life Sciences.
Signup to Generate a PitchThe Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to stay up to date and inspired in their daily work.
Leaders in Life Sciences is hosted by Dr. Kesha Chauhan, MD. The show has published 31 episodes to date.
Recent episodes include "29: Another Recall for Glenmark: Millions of Bottles of Generic ADHD Drug Pulled" (17 March 2025, 5 minutes), "28: Novo Nordisk's Bold Leap into Rare Diseases" (12 March 2025, 9 minutes), and "27: FDA Updates Labeling and Safety Information For Testosterone Products" (5 March 2025, 6 minutes).
Leaders in Life Sciences publishes roughly weekly, with episodes averaging 8 minutes across 31 episodes.
Booking probability for Leaders in Life Sciences is 29%, and the host is rated Selective on guests. Leaders in Life Sciences requires a Pod Score of 80 or higher. Leaders in Life Sciences's contact route on record: verified email.
The strongest fits for Leaders in Life Sciences are Scientific Research & Development. Leaders in Life Sciences has a science audience.
Dr. Kesha Chauhan, MD hosts Leaders in Life Sciences, a science podcast with 31 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Leaders in Life Sciences
Glenmark Pharmaceuticals has recalled nearly 1.5 million bottles of generic atomoxetine (ADHD medication) due to unacceptable levels of a potential carcinogen, N-nitroso atomoxetine. This recall, from January 2024, adds...
Leaders in Life Sciences
Novo Nordisk is strategically expanding into rare diseases, shifting from its traditional focus on common chronic conditions, by significantly increasing R&D investment and executing key acquisitions to build a strong...
Leaders in Life Sciences
<p>The FDA is updating the labeling for all FDA-approved testosterone products (oral, topical gel, transdermal patch, buccal system, and injection) based on the TRAVERSE trial and ABPM studies. The results of the...
Leaders in Life Sciences
A study by Phreesia demonstrated that point-of-care messaging significantly increases vaccine uptake. Patients who received vaccine information prior to their appointments were more than twice as likely to get...
Leaders in Life Sciences
In 2024, Moderna faced financial challenges including $739 million in cost of sales for the fourth quarter, which factored in $193 million in inventory write-downs, $259 million in production wind-down costs, and a $238...
Leaders in Life Sciences
<br><br /><p > Hosted on Acast. See acast.com/privacy for more information.</p>
Leaders in Life Sciences
<p>The pharmaceutical and life sciences sector anticipates a surge in merger and acquisition activity in 2025. Driving this trend are expected interest rate reductions by the Federal Reserve and the resolution of...
Leaders in Life Sciences
<br /><p > Hosted on Acast. See acast.com/privacy for more information.</p>
Leaders in Life Sciences
<p>The FDA is alerting the public to the risk of anaphylaxis, a rare but serious allergic reaction, associated with glatiramer acetate (Copaxone, Glatopa), a drug used to treat multiple sclerosis (MS). Anaphylaxis can...
Leaders in Life Sciences
Novo Nordisk, known for its obesity drugs Ozempic and Wegovy, reported strong profit and revenue for 2024, surpassing Wall Street expectations. However, the company expects slower sales growth in 2025 due to rising...
Leaders in Life Sciences
Pfizer is heavily investing in its experimental obesity drug, danuglipron, aiming for a once-daily oral pill to compete with the currently dominant injectable weight-loss treatments from Eli Lilly and Novo Nordisk. CEO...
Leaders in Life Sciences
Swoop, an AI-driven healthcare marketing business, acquired MyHealthTeam, a company that runs condition-specific online patient communities1. MyHealthTeam has over 60 communities, some with over 100,000 members, focused...
Leaders in Life Sciences
<p><br></p><p>The FDA will require GSK and Pfizer to include a warning about the risk of Guillain-Barré syndrome (GBS) on the labels of their RSV vaccines, Arexvy and Abrysvo, respectively. This decision was made after...
Leaders in Life Sciences
The future of pharmaceutical marketing is poised for significant change, driven by technological advancements, a focus on the patient, and sustainability. The integration of cutting-edge technologies like AI, machine...
Leaders in Life Sciences
The FDA has approved Ensacove (ensartinib), a new second-generation ALK inhibitor, as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC) in patients who have not previously received an ALK...
Leaders in Life Sciences
The FDA initially authorized COVID-19 tests through Emergency Use Authorizations (EUAs) to facilitate their rapid deployment during the pandemic. These tests can continue to be used as long as they are available and not...
Leaders in Life Sciences
The pharmaceutical industry is facing significant challenges and must undergo a bold reinvention to ensure its future success. The sector's shareholder returns have been lagging behind the broader market, with a...
Leaders in Life Sciences
Citius Oncology is preparing to launch LYMPHIR™, a novel treatment for cutaneous T-cell lymphoma (CTCL), and is simultaneously exploring strategic options to maximize its market impact. These options include...
Leaders in Life Sciences
Johnson & Johnson's Rybrevant and Lazcluze drug combination shows significant improvement in overall survival for patients with EGFR-mutated non-small cell lung cancer compared to the current standard treatment...
Leaders in Life Sciences
This podcast episode discusses Ozempic (semaglutide), a GLP-1 receptor agonist initially used for type 2 diabetes, now gaining popularity for weight loss. The episode details its mechanism of action, effectiveness...
PitchCentric classifies Leaders in Life Sciences under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
